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Abstract This article presents two cases of policymaking concerning the vaccine against
Human Papilloma Virus (HPV), which is sexually transmitted and carcinogenic. Our
analysis focuses on its introduction in Austria and the Netherlands. In both contexts,
we ﬁnd prevention and screening to be at once complementary and competing
public health logics and we draw on the concept of ‘infrastructure’ to understand
their roles in shaping the reception of the vaccine. We reveal how the HPV vaccine
had to be made ‘good enough’, much like the Pap smear (Casper and Clarke 1998),
by means of diverse tinkering practices that transformed both the technology and the
infrastructures in which they emerged. At the same time, it was important that the
vaccine would not come to problematise Pap smear-based screening. The article
points to the contextually contingent nature of policymaking around new medical
technologies, and the skillful care with which public health infrastructures such as
immunisation and screening programmes are handled and tinkered with.
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Introduction
Much like screening (Armstrong and Eborall 2012), preventive technologies appeal to policy-
makers, medical professionals and public health authorities, yet they are often received
critically by target groups (Hobson-West 2007, Reich 2016). The vaccine against Human
Papilloma Virus (HPV), which is sexually transmitted and widespread, is a case in point: First,
in the early 2000s, medical researchers saw the development of a vaccine against some strains
of the carcinogenic virus as a real breakthrough, heralding it as the ‘ﬁrst vaccine against can-
cer’ (Gericke 2008, cited in Paul 2016: 193). Yet these hopes were not only premature but
highly contested, as sociologists have documented extensively (cf. Casper and Carpenter 2008,
Epstein 2010). Second, the vaccine unsettled established ways of cancer-screening using the
Pap smear, which now came to be reconsidered in light of a newly emerging HPV-based para-
digm – for over 90 per cent of cervical cancer was found to be causally related to strains of
HPV. The vaccine thus had to make room for a new role as a preventive tool among current
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concepts of public health and related professional as well as institutional traditions. In this
paper, we ask: How did the HPV vaccine put extant public health programmes to the test and
with what effect?
To our knowledge, the competing logics (e.g. Mol 2008) – or, as we view them, ‘infrastruc-
tures’ (Star and Ruhleder 1996) – of screening and prevention have not been addressed in the
state of the art on HPV policy. Extant scholarship either focuses on issues of gender, sexuality
(or, rather, its exclusion), and pharmaceutical interests (Casper and Carpenter 2008, Mamo and
Epstein 2014, Wailoo et al. 2010), while the emergence of HPV-based screening has mainly
been studied in the context of a wider trend of ‘molecularisation’ (Hogarth et al. 2012). For
sociologists of immunisation, on the other hand, HPV has not been a focus as their research
typically addresses resistance against ‘regular’ childhood vaccines (Blume 2006, Hobson-West
2007, Reich 2016).
This disconnect between studies of HPV prevention and HPV-based screening is puzzling
given the impact of the vaccine on, if not conﬂict with, public health programmes across coun-
tries (Paul 2016): Not only did the HPV vaccine have to match legal, social, and technical
requirements of national immunisation programmes (NIPs) grappling with recurrent waves of
vaccine hesitancy (Reich 2016); it also had to be integrated alongside historically established
screening programmes. The success of screening had been celebrated as key milestones in
women’s health (Casper and Clarke 1998), yet now HPV vaccination was making similar pro-
mises to revolutionise women’s health. These promises and potentials produce divergent inter-
pretations, concerns and policies across countries. In the study of such diversity (Aarden et al.
2011), the prominent ‘coproduction’ paradigm (Jasanoff 2004) has been immensely instructive
in cross-national analyses, yet it pays little attention to conﬂict and negotiation, unlike critical
policy studies (Wagenaar 2014). Inversely, critical policy scholars have yet to reﬁne concep-
tual understandings of (emergent) technologies (cf. Uttley 1991).
In view of these gaps, this paper presents a comparative qualitative analysis of the emergence
of the HPV vaccine in two countries, Austria and the Netherlands. Both countries feature a pub-
licly funded health care system with voluntary, and tax-funded participation in vaccination as
well as screening, and universal coverage based on the principle of equal access. Yet the HPV
vaccine emerged at different time points and was backed by different implementation strategies –
for example, target groups of HPV vaccination differed by gender and age. To understand these
differences, we explore how HPV-based technologies came to be integrated into existing public
health infrastructures and how they exposed their shortcomings at the same time. In this sense,
our comparative approach cuts across two axes of difference: ﬁrst, country-based differences,
and second, infrastructural differences within those cases (i.e. screening and prevention). Based
on desk research, interviews (n = 21, see appendix online), and secondary analysis of earlier
observations, our analysis documents the ‘infrastructural frictions’ that occurred, ﬁrst, between
the novel vaccine and national immunisation programmes (NIP), and, second, the friction – and
eventual realignment – between NIP and screening infrastructures already in place. The next
section explicates our object of analysis and discusses the extant literature, while the third section
begins to unfold what we label an ‘infrastructural approach’. The fourth section presents the two
country-based cases, and the ﬁfth section discusses the ﬁndings in light of our comparative
approach and our contribution to the extant literature.
A contested vaccine: towards a new approach
Cervical cancer is the second most common cause of cancer-related death in women world-
wide (Boulet et al. 2008), despite the success of screening programmes employing the Pap
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smear test, named after its designer Georgios Papanicolaou. The discovery of a causal link
between some strains of HPV and cervical cancer in the 1990s led to diagnostic and preven-
tive technology development, which culminated in the approval of two vaccines, in 2006 and
2007, respectively by the United States Food and Drug Administration (FDA) and the Euro-
pean Medicines Agency (EMA). Critical observers raised a variety of economic, ethical, and
societal objections to the novel vaccine. The notion of immunising children against a sexually
transmitted infection was received with some opposition both in North America and Europe
(Connell and Hunt 2010, Epstein 2010). Conservatives feared that young girls could be ‘sexu-
alised’ through the vaccine, and parents’ beliefs often reﬂected this discourse (Reiter et al.
2009). Feminist critics questioned the gendered nature and impact of the vaccine on women’s
lives (Casper and Carpenter 2008, Mara 2010, Mishra and Graham 2012). Health economists
embarked on complex modelling exercises in attempts to estimate the cost effectiveness of the
new, and rather cost-intensive vaccine. When studies began to indicate that men could not only
contract genital warts through HPV infection, but could also develop penile cancer, anal cancer,
and cancer of the neck, gay activists in the US began to lobby for administering the HPV vac-
cine to men too (Epstein 2010) – as did scholars who objected to the gendered and heteronor-
mative nature of HPV campaigns. Some experts, in turn, questioned the long-term effectiveness
of the vaccine and warned against false feelings of safety and protection as the vaccine protects
against certain HPV-types only (Adams et al. 2007); it could thus not replace Pap smear-based
screening programmes. Finally, commentators accused the pharmaceutical industry of ‘pushing
too hard’ for the endorsement of the vaccine in NIPs and concealing uncertainties regarding
long-term effectiveness and side-effects. In sum, the HPV vaccine was not only promising that
it could, for the ﬁrst time, help prevent cancer, but was also highly contested.
The efforts we observed in HPV policymaking are reminiscent of historical efforts to make
the Pap smear ‘good enough’ and ‘the right tool for the job’ (Casper and Clarke 1998, Paul
2016). This means that much like the Pap smear, the HPV vaccine did not only have to fulﬁl
technical criteria, but also come to satisfy pertinent ‘social worlds’ to become embedded in
them (Clarke and Star 2008, Paul 2016). In the case of the HPV vaccine, the social worlds of
both cervical cancer screening and immunisation were involved, and included clinicians, poli-
cymakers, parents’ groups, and women’s health advocates. In adopting and adapting to these
different social worlds, the HPV vaccine was reshaped to match historically contingent infras-
tructures of public health and simultaneously changed those very infrastructures. Given these
conceptual premises, our research question then becomes: How did the HPV vaccine put
extant public health programmes to the test and with what effect? Below, we further develop
this conceptual argument in the context of an ‘infrastructural approach’ to policy, thus bringing
together insights from critical policy analysis and science & technology studies (STS).
An infrastructural approach to vaccination policy
The renewed importance of virology and the uncertainties around the vaccine had implications
not only for prognosis, but also for policy infrastructures that predated the HPV-paradigm. In
line with STS, we propose that technologies are actively shaped and reshaped to ‘ﬁt’ into a
particular infrastructure and need to make room for themselves among prevailing concepts,
institutions, and power relations (L€owy 2010). This entails conﬂict and negotiation, as docu-
mented in the establishment of the Pap smear (Casper and Clarke 1998). In this ‘becoming
good enough’, technologies may undergo reshaping and reworking, and their deﬁcits become
concealed when they come to be temporarily stabilised (cf. Singleton 1998, Singleton and
Michael 1993). This reshaping by and in context is, of course, contingent upon prevailing
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institutions and practices at a given time, in a given place. Accordingly, in our situated com-
parative approach, we remain sensitive to the speciﬁcities of the two political contexts and
their historically shaped, and contextually contingent public health policy infrastructures. Our
study thus adds not only to our understanding of HPV policy, but to an appreciation of how
new technologies ‘put infrastructures to the test’ across (national) contexts.
In our understanding of the impact of the HPV vaccine and its interaction with the NIP, the
concept of infrastructures is key (e.g. Bowker and Star 2000). Infrastructures are commonly
described as substrates: something upon which something else ‘runs’ or ‘operates’ (Schick and
Winthereik 2016, Star and Ruhleder 1996). Thus they carry a more material and stable conno-
tation than Mol’s (2008) notion of a ‘logic’. Yet STS scholars have highlighted the relational
connotation of infrastructure, underscoring how infrastructures mediate exchange over distance,
bringing different people, objects and spaces into interaction and forming the base on which to
operate economic and social systems (Larkin 2013). Hence, infrastructures are informative
objects of study, in the sense that they only become real in relation to practices (Star and Ruh-
leder 1996) – organisational or other.
Likewise, the HPV vaccine becomes acutely real and meaningful – that is, of different mean-
ings to different social worlds – when we try to place it in the infrastructural context of NIPs,
the invested social worlds, and the practice of public health. Recent work in STS has empha-
sised that infrastructures, while purely technical in the public imagination (Bruun and Morita
2015: 82), are fundamentally social. Bruun and Morita (2015: 83) add that infrastructures are
ﬂuid and dynamic entities, that their components are subject to change, ‘but also the forms of
politics, society and environment generated by these systems’. Infrastructures thus entail and
produce new forms of politics, agency, and sociality (Bruun and Morita 2015). Immunisation
programmes – including vaccination registries, surveillance, research, and street-level public
health workers – are a case in point. Our theoretical argument is hence two-fold: ﬁrst, when a
new medical technology emerges, it is not only shaped by the institutional context in which it
emerges, but transforms it at the same time. We capture this interaction between technology
and context as one of ‘infrastructural friction’. Second, we conceptualise NIPs as infrastructures
that at once represent particular sociotechnical orders and actively produce such orders.
We thus view infrastructures – here, that of the NIP and its counterpart, the cervical cancer
screening programme – as dynamic, but sociomaterial entities composed of multiple compo-
nents, including technologies and ways of doing things (e.g. vaccination plans, Pap smears). In
this sense, public health infrastructures are contingent entities that hold and serve to both
enable and protect technologies and tools that are ‘good enough’ (Casper and Clarke 1998) at
certain spatial-temporal moments. Introducing new elements, in turn, causes ‘infrastructural
friction’, and in our present case, transformation and realignment.
Research design
To examine how institutional friction plays out differently across the two contexts of Austria
and the Netherlands, we draw on three sources. First, the infrastructural approach required
desk research on professional responsibilities, institutional relations in public health, and docu-
ments such as vaccination plans and screening guidelines. Second, we conducted in-depth
interviews (n = 21, see appendix online), with public health ofﬁcials, clinicians, and research-
ers in both countries, using both the desk research to identify the experts and, subsequently,
the snowball method. The Austrian case study, presented elsewhere in a different form (Paul
2016), was undertaken by author 1. The Dutch case was executed by all three authors. All
interviews, which lasted one hour on average using individual interview guides, were recorded
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and transcribed verbatim after permission from the respondents. We obtained narrative
accounts of policymaking with a focus on practices, but also explored, for instance, the mutual
positioning of social worlds, and what respondents perceived to be key events. Third, we draw
on a secondary analysis of data collected in an earlier participatory ethnographic study of the
introduction of HPV vaccination in the Netherlands in which we engaged in the assessment of
HPV vaccination for the Dutch Immunisation Programme at the Centre for Infectious Disease
Control (Centrum Infectieziektebestrijding, CIb), part of the National Institute for Public Health
and the Environment (Rijksinstituut voor Volksgezondheid en Milieuhygi€ene, RIVM) (Wallen-
burg and Bal 2008). We interviewed the respondents again (late 2014-early 2015) to gain
insights concerning the emergence of the HPV vaccine over time. This diachronic approach
allowed us to develop a particular ‘ethnographic sensitivity’ (Prainsack and Wahlberg 2013) to
the role of political spaces (institutions, policies, online and ofﬂine media, school yards, public
health centres) in the making and remaking of policy infrastructures. Accordingly, the analysis
below presents an account of infrastructural interaction with the vaccine, rather than individual
agents’ accounts.
New vaccines and old infrastructures: creating a ‘good enough ﬁt’
Public health in Austria1
In September 2007, the Supreme Health Council (OSR), an advisory committee to the Min-
istry of Health (MoH), released a non-binding recommendation of HPV vaccination for girls
and boys in Austria. Shortly afterwards, a young girl died a few weeks after her HPV vaccina-
tion, and a debate began to emerge, featuring concerns of vaccine safety and calls to review
the NIP prior to adding any new vaccines – for example, by improving data collection in vac-
cination registries. In what we interpret to be an attempt to depoliticise the emerging vaccina-
tion debate, the Minister of Health, Andrea Kdolsky, commissioned a health technology
assessment (HTA) report, labelled as an ‘economic evaluation’ of the vaccine. The HTA report
solidiﬁed the earlier ministerial stance that the safety and effectiveness of the vaccine had yet
to be proven (Paul 2016). In addition, it recommended investing more heavily in improving
the screening programme – responding in part to criticisms by women’s health advocates, but
arguably equally so to concerns about safety, long-term effectiveness, and ﬁnancing. The Min-
ister decided not to include the vaccine in the NIP – quite in contrast to her European counter-
parts. What can we learn from this episode – which, as we shall see below, was only one of
many moments of Austrian HPV policy – about Austria’s public health infrastructure?
To begin with, Austria features a federalist social health insurance system; vaccination in
the NIP is voluntary and tax-funded. The aforementioned advisory committee (OSR) meets
regularly and publishes annual updates, yet its modus operandi appears less transparent than
its European counterparts. The cervical screening programme is institutionally separate, but
opportunistic as much as the NIP is: it relies on individual patients’ initiative, rather than a
call-recall system. Despite frequent criticism and known weaknesses in Pap smear reading
(Singleton 1998), quality assurance is not compulsory (Rasky et al. 2013, Interviews 6 and 7).
Notwithstanding Austria’s small size, its federal states share competencies with the federal
government in public health. The NIP similarly features this intricacy, for implementation of
the NIP is handled at the level of federal states (Paul 2016). A vaccination pass is stapled into
the ‘mother child health pass’ (MCHP) – yet while completing particular antenatal and pedi-
atric consultations documented in the latter is linked to receiving beneﬁts, immunisation is not.
1The discussion of the Austrian case draws strongly on Paul (2016).
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The sociotechnical design of the MCHP does, however, invoke the notion of parental responsi-
bility.
Vaccination rates, however, are comparatively low in Austria, with only 76 per cent of
infants being immunised against MMR (OECD 2015). Opposition to vaccination is not limited
to religious objections, but includes views of immunisation as an unnatural interference in the
course of childhood, fears of ‘unnatural’ adjuvant substances, and prevalent beliefs that vacci-
nation may cause allergies (OTS 2013, Interview 1, Paul 2016). Moreover, low vaccine uptake
may be related to the fragmented immunisation infrastructure, where no call-and-recall system
exists. Vaccines in the Austrian NIP are administered in multiple sites, including local public
health centres and schools, yet school doctors are not obliged to, nor insured for, vaccinating
children in federal public schools (Bundesschulen). This once again reveals that the Austrian
public health infrastructure strongly relies on individual efforts (i.e. those of parents, profes-
sionals, school directors), in contrast to the solidiﬁed, programmatic nature of Dutch public
health infrastructures, where the state guides and directs public health action in a more rigid
manner while maintaining the notion of choice, as we will point out in more detail below.
Adapting and adopting the vaccine in Austria
What implications did this fragmented infrastructure and politically sensitive nature of vaccina-
tion in Austria have for HPV policy? In early 2008, as mentioned above, the Minister of
Health decided to reject the inclusion of the vaccine in the NIP based on ﬁnancial arguments
and concerns regarding safety. This speaks to a shift in public narratives where the risks of
vaccines are seen to outweigh their beneﬁts (Berezin and Eads 2016). Yet while vaccine devel-
opers continued to tinker with and study the HPV vaccine, room was made for it in Austria’s
public health system, using a different path. First, HPV researchers broke new ground when
results suggested promising effectiveness for the prevention of anal cancer, the incidence rates
of which had been growing in both women and men who have sex with men. Similarly, head
and neck squamous cell carcinoma, a disease previously largely attributed to environmental
exposures, was now linked to infection with some strands of HPV. Clinical researchers at the
Medical University of Vienna continued to disseminate this evidence and were themselves also
involved in clinical trials (Interview 7, Paul 2016).
Second, regional policy experiments with subsidising the vaccine were initiated in 2007 and
2008 to enrol local support. These regions functioned as a testing bed for the societal response
to the HPV vaccine, yet these policies also reafﬁrm the fragmented nature of the NIP. Third,
the vaccine’s supporters – key MoH ofﬁcials and clinical researchers – continued to actively
collect and disseminate evidence in support of the HPV vaccine in relevant networks within a
tightly knit policy community. Inviting experts from abroad to exclusive seminars at the MoH
added to the notion that more ‘objective’ data was being collected in this phase. HPV policy
was discursively managed as an expert debate, rather than one that required public debate. In
our interviews, critics of the HPV vaccine, such as feminists, were positioned as anti-vaccina-
tionists (‘Impfgegner’, Interviews 1, 2 and 7) or as insufﬁciently knowledgeable due to their
lack of clinical expertise (Interview 7, Paul 2016).
In turn, key policy ofﬁcials in charge of vaccination at the MoH sought to counter further
problematisation of the NIP. Now headed by Minister Alois St€oger, considered generally in
favour of HPV vaccination (Interview 1), the MoH strengthened the NIP by adding two nota-
bly less contentious vaccines in 2012, against pneumococcal and meningococcal infections.
Policy ofﬁcials also tinkered with the infrastructure by investing in a more visible construction
of the importance of the HPV vaccine: statistical surveillance of HPV infections in Austria
began to explicitly and equally refer to women and men, and all cancers caused by HPV (Paul
2016: 197). This meant that the vaccine was being discursively detached from women’s bodies
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alone and helped construct a shared, rather than gendered need for the vaccine. Hence, the
HPV vaccine served a much wider public, adding to the Pap-based screening instead of com-
peting with it. While also other vaccines, such as MMR (Dew 1999) have relied on such visi-
ble constructions and quantiﬁcations, the gendered aspect of the HPV vaccine, we ﬁnd, takes a
particular kind of infrastructural tinkering. At the same time, the vaccine was being removed
further from gynaecologists who, in media reports (Paul 2016, cf. St€ockl 2010), had been per-
ceived as too entangled with the pharmaceutical industry.
Furthermore, evidence emerging in 2010 and onwards (Schiller et al. 2012) suggested that
administering two, rather than three doses, offered adequate protection, making the vaccine
less of an organisational and ﬁnancial burden (Interview 7), and assuring the feasibility of
school-based delivery (Interview 13). Furthermore, the cost of the vaccine decreased signiﬁ-
cantly, while its prophylactic range had grown and it had already been licensed for administra-
tion to children as young as 9 years old. Put differently, by 2013, the HPV vaccine had (been)
turned into a product that was rather different from the vaccine discussed in 2007 (Paul 2016).
In August 2013, the Minister of Health announced: ‘We have expanded the free children’s
vaccination programme step by step. I am certain that, with the inclusion of the vaccine
against HPV, we will be offering an essential contribution to the health of our children. We
will save lives.’ (BMG 2013; cited in Paul 2016: 197). Enhancing the effectiveness of this
statement, the decision was presented as beneﬁcial to all. To underscore the general support of
public health, the inclusion of the HPV vaccine was announced by three key public health
players: the Minister of Health; Pamela Rendi-Wagner, the director of public health at the
MoH and immunologist by training; and the President of the patient association Krebshilfe,
Paul Sevelda, who also practices gynaecology. The vaccine would be offered to all children as
young as 9 years old and the minister highlighted the innovative, gender-neutral nature of Aus-
trian HPV policy. This newly invoked understanding of the HPV vaccine as a ‘regular’ child-
hood immunisation also implied that professionals typically considered trustworthy –
pediatricians – could deliver the vaccine. Thus, not only was the vaccine desexualised, but its
infrastructure (i.e. the designated administrators of the vaccine) had been transformed, too.
Gynaecologists were no longer in charge of HPV vaccination (Paul 2016).
The HPV vaccine is now administered in schools or in private practices by pediatricians
and GPs. Direct parental consultation can largely be by-passed in school-based vaccination, or
at least formalised in standardised health status questionnaires and a parental consent form.
Yet any questions or concerns children may have regarding HPV and sexual transmission are
compartmentalised to a professional pediatric setting, much like the Pap smear is in gynaeco-
logical practices (Paul 2016). Turning the HPV vaccine into a regular vaccine made it ‘good
enough’ for public health in Austria.
At the same time, the fragmented nature of the NIP was left intact, and the renewed vacci-
nation policy discourse focused on maximising vaccine uptake and providing information, or,
as in the recent campaign for the MMR vaccine, with fear-inducing slogans. This way, opposi-
tion to HPV vaccination was easily sidelined as irrational, including that of experts in the ﬁeld,
such as the HTA community, and those public health experts calling for structural reforms to
the NIP prior to any additions. Likewise, the cervical cancer screening programme was left
unreformed, screening continues to be opportunistic, and – a number of dispersed quality
improvement projects aside – quality assurance of the Pap smear remains a matter of profes-
sional associations, in line with the high degree of professional autonomy in Austria. Nonethe-
less, the gender-neutral approach of its HPV policy enabled policy ofﬁcials to label the
Austrian NIP as a ‘European frontrunner’ in HPV policy – concealing the experienced difﬁcul-
ties in making the vaccine ‘good enough’ over a period of seven years, as well as the frag-
mented nature of the NIP and screening infrastructures.
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Public health in the Netherlands
Given the highly institutionalised role of the youth health services and the programmatic
approach of vaccine policies, most parents perceive immunisation as something quasi-compul-
sory in the Netherlands. Likewise, the Dutch cervical cancer screening programme is based on
a call-recall system, and cervical cancer is less common in the Netherlands than in most other
countries (Gezondheidsraad 2011).
Vaccine uptake is comparatively high, with 96 per cent of infants being vaccinated against
MMR (OECD 2015; cf. RIVM 2006) despite its voluntary nature, and to public health ofﬁ-
cials, protecting this high uptake is of utmost importance. Nonetheless, also here, a small, yet
identiﬁable segment of the general population opts not to have their children vaccinated. First,
traditional orthodox Protestant communities, and second, a more recent movement of so-called
‘critical parents’ refusing vaccination out of fear for side effects and adverse reactions, or the
belief that vaccination may impair the developing immune system (Blume 2006, Streeﬂand
2001). These parents are typically associated with higher levels of education (Veldwijk et al.
2015). While often labelled irrational in our interviews with policymakers (interviews 10 and
15) and observations of scientiﬁc deliberations, this subcommunity is nonetheless included in
the NIP: anthroposophical health centres cater to their wishes for alternative vaccination sched-
ules (Interview 16; Geelen et al. 2016, cf. Cunha and Durand 2013). This exempliﬁes the
highly programmatic and thoroughly organised nature of the Dutch NIP – unlike its oppor-
tunistic and loosely organised counterpart in Austria.
We propose to understand this feature of the Dutch NIP as one of ‘organised diversity’,
which is likely to increase vaccine uptake as it embeds deviance from the norm in governmen-
tal practice. Second, we propose that the underlying infrastructures, which have been treated
largely empirically, not theoretically, in the existing literature (Blume 2006, Geelen et al.
2016, Horstman 2013), are key biopolitical technologies that deserve greater attention. For
instance, the vaccination registry Praeventis allows for individual level recording of vaccine
uptake as well as epidemiological surveys of both vaccinated and non-vaccinated populations
(van Lier et al. 2012). It thus not only enables the prediction of likely outbreaks in regions
where, due to for example, religious afﬁliation with Christian orthodoxy, vaccination uptake is
low, but also makes it virtually impossible to ‘avoid’ the NIP, unlike in our Austrian case.
Below, we highlight the similarly programmatic character of Dutch HPV policy and cervical
cancer screening.
From ‘rolling out’ to ‘weaving in’
In the Austrian case, early HPV policy rejected the vaccine because of its novel, uncertain,
costly, and politically sensitive character – in short: it was seen as a vaccine different from
others. Yet in the Netherlands, early HPV policy did not highlight its different character, but
rather treated it as a vaccine just like any other that could be effectively ‘rolled out’ in the
well-established and programmatic public health infrastructure. This public health infrastructure
largely focuses on the effectiveness of public health measures – both in terms of biomedical
effects (‘protection’ and ‘health improvement’) and cost-effectiveness. To this end, a robust
policy infrastructure has been established: It includes, ﬁrst, a scientiﬁc advisory committee at
the Health Council (providing ‘state of the art’ scientiﬁc advice on biomedical effectiveness
and cost-effectiveness) and second, a research and executive agency in the form of the Centre
for Infectious Disease Control (Centrum Infectieziektebestrijding, CIb) at the RIVM that, in
collaboration with the Health Council, advises the MoH on (the adaption of) vaccines for the
NIP, and monitors vaccine uptake and effectiveness. The assumption underlying this infras-
tructure is that if (cost) effectiveness is proven and the NIP is scientiﬁcally monitored and
robust, citizens will trust expert advice and partake in the programme. This programmatic
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approach also becomes apparent in the administration of vaccines: infants (age 0–4 years) are
vaccinated during regular health and development check-ups. Parents are invited to these visits,
and in case of a no show, receive a reminder, and/or a house visit. Other age groups are
immunised in cohorts at local sports halls, making vaccination a public and collective event,
quite in contrast to the private and individual nature of the choice for vaccination.
In line with this programmatic approach, Ab Klink, then Minister of Health, commissioned
a vaccine assessment from the Dutch Health Council for HPV vaccination. Simultaneously,
the CIb was commissioned to assess the possibility of introducing HPV vaccine in the NIP in
2006. Our participant observations of the committee tasked with identifying the appropriate
criteria to assess the HPV vaccine at the CIb (2006–2007) showed that concerns regarding
societal responses and its uncertain long-term effectiveness played a role, too, besides antici-
pated costs and effectiveness (Boot et al. 2008). Moreover, the committee was careful to, on
the one hand, consider the HPV vaccine as a new way of protecting against cervical cancer,
while, on the other hand, avoiding a problematisation of the screening programme. Both NIP
and screening programme were considered well-functioning public health programmes with
high levels of trust presumed. Similarly, the Health Council used established criteria to evalu-
ate the vaccine for the NIP, reﬂecting a very programmatic approach: severity and extent of
the disease, effectives, acceptability, effectiveness, and priority of the vaccine (Gezondheid-
sraad 2008). This procedure underscores the expert-based paradigm underlying the Dutch NIP.
For instance, the Health Council as well as the CIb committee discussed the target group of
the vaccine (girls, boys, age groups), organisation of vaccination (schools or local public
health providers), the possible need for booster vaccination, the desirability of a catch-up pro-
gramme, and the impact of the vaccine on participation in the national screening programme
for cervical cancer (Boot et al. 2007). Following deliberations of nearly one year, the Health
Council published a 200-page report in favour of HPV vaccination (Gezondheidsraad 2008).
The MoH, which had already announced it was to follow the Council’s recommendation
(Interview 21), quickly adopted the advice and included the HPV-vaccine for girls of 12. In
addition, a catch-up programme was announced for girls 13–16 years old to enable a higher
protection rate.
How do these assessment practices compare to the Austrian case? The Dutch Health Council
regularly publishes lengthy reports on its activities and assessments, displaying its transparency
regarding vaccination policies – quite in contrast to its Austrian counterpart. Furthermore, in
the case of HPV, representatives of the pharmaceutical industry but also a representative of the
‘critical parents’ movement mentioned above (Nederlandse Vereniging Kritisch Prikken,
NVKP) were invited to attend parts of the deliberation and to provide input. Beyond its partic-
ipatory quality, this policy practice, we propose, once again points to the anticipatory mode of
vaccination policy in the Dutch context. At the same time, it brings to the fore a rather techno-
cratic practice in which a mechanism for voicing (Hirschman 1970) was introduced to not only
hear, but, perhaps to manage the anticipated opposition, as is regular practice in the Council
(Bijker et al. 2009). Finally, as witnessed in our observations in 2006–7, among HPV advo-
cates, there was ‘always a consensus that the vaccine was good in itself’ (Interview 21) even
prior to formal evaluations, given its potential to ‘save 200 lives per year, which is a relatively
high number for an infectious disease’ (Interview 21). This indicates the dominant causal fram-
ing of cervical cancer and HPV, the meaning of the vaccine as a tool to prevent an infectious
disease, and ﬁnally, the idea that the vaccine was ‘good enough’.
With the vaccine considered ‘good enough’ early on, what kind of work needed to be done
in Dutch HPV policy? While Austrian HPV policy invested – over a period of seven years –
in tinkering with the vaccine, largely leaving the extant infrastructure untouched – Dutch HPV
policy was not to invest in making the vaccine good enough, but rather to prevent
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‘infrastructural friction’ with the NIP. This second phase of HPV policy consisted of institu-
tional tinkering: HPV vaccination was moved to the general public health system in charge of
prevention, the Public Health Services (PHS), thus setting HPV apart from the NIP, which is
designed for children up to the age of 9 years. Policy ofﬁcials were hesitant to review or even
amend a well-functioning NIP as not to risk losing public trust and the comparatively high
uptake of vaccinations in general (Interviews 17 and 18). Overall, the two cases thus feature
opposing tinkering strategies: ultimately, Austrian policy transformed the vaccine into a regular
vaccine, and Dutch policymakers accentuated its difference while trying to anticipate and
soothe opposition in quasi-participatory practices.
More speciﬁcally, we propose, this approach reﬂects an expectation that the extant infras-
tructure would do the adaptation work for them: Dutch HPV policy relies on a ‘rolling out’
approach, driven by a more general technocratic, expert-based policy approach. This approach
typically relies on framing public concerns as lay perceptions of expert matters requiring either
a technical ﬁx, or science-based monitoring. Yet this ‘rolling out’ approach through regional
public health providers within the PHS soon proved inadequate for the HPV vaccine. Two
issues emerged, with unexpected consequences for HPV policy. First, the RIVM embarked on
a strongly gendered HPV campaign that focused on girls and their mothers, with an underlying
appeal to making the ‘right’ choice. This approach turned out not to fare well in a time where
social media, particularly the Dutch platform Hyves – at that time a popular Dutch version of
Facebook – emerged as a new communication technology among teenagers. For the ﬁrst time,
the NIP included a vaccine that was not only to be discussed with parents, but that formed a
matter of concern among young girls and their parents. It was also discussed and contested
ofﬂine, at kitchen tables and in schoolyards – and led to an unprecedented amount of girls
refusing vaccination. In other words, the felt need for public engagement and the gendered nat-
ure of the RIVM campaign backﬁred.
A second issue in early Dutch HPV policy that ampliﬁed public hesitance, was its ﬁrmly
expert-driven nature, and particularly the felt need for a scientiﬁc consensus in order to protect
the robustness of the NIP. We understand this dominant status allocated to biomedical knowl-
edge as a resource for depoliticisation – much like the economisation of the vaccine by means
of a unique HTA report was in Austria. The Dutch consensus-driven approach, however, failed
when dissenting experts publicly articulated doubts regarding the safety and long-term efﬁcacy
and effectiveness of the HPV vaccine in 2008 (de Kok et al. 2008). Individual experts, partic-
ularly clinical gynaecologists, publicly raised their voice against HPV vaccination, underscor-
ing the vaccine’s uncertainties and arguing for more effective and less costly measures against
cervical cancer, like improving the existing cervical cancer screening programme (Interviews
20 and 21). This points to the friction that occurred between screening and vaccination infras-
tructures, in addition to infrastructural friction within each of those with the emergence of
HPV diagnostics and prevention. The fact that these same critics were involved in screening
infrastructures – not only as advocates, but as their active administrators – illustrates the fric-
tion between the two infrastructures particularly well.
What made these public appearances even more meaningful for HPV policy in the making
was the membership of one of the scientists in the Health Council, albeit not on the cervical
cancer committee itself, but as a member of the Council’s Standing committee on Health law
and ethics. She was publicly accused of harming public faith in the vaccine, and with that,
trust in the NIP. In that sense, the dissenting experts’ position can be understood as instances
of what Michael (2012) discusses as ‘overspilling’ the political framing of an event, or as
‘misbehaviour’; those activities or actions that do not make sense within the framing of the
engagement event, but actually disturb the collective engagement – in this case, the creation of
a shared understanding of the goodness of the vaccine for the NIP.
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What consequences does such ‘misbehaviour’ (Michael 2012) generate in the pertinent
infrastructure? In response to the public appearance of critical experts, leading public health
ofﬁcials criticised this group of scientists heavily, suggesting that they had broken a silent
agreement to only voice dissent behind closed doors (Interviews 19 and 21). In Austria, policy
ofﬁcials had managed to silence opposition by marginalising their critique, and positioning it
as ideological and scientiﬁcally unfounded. In the Dutch context, on the other hand, the very
employment of the scientiﬁc method – publications in journals, employing numbers, perform-
ing expertise – helped to set the stage for not only a public, but also a scientiﬁc controversy.
Given the failure of the consensus-driven, rolling-out approach, how was the HPV vaccine
accommodated eventually, and with what transformative effects on the pertinent infrastruc-
tures? Neither the NIP nor the screening programme remained unaffected by the HPV vaccine.
First, the RIVM campaign shifted in its communication regarding HPV (Interviews 15,16 and
18). Guided by consultants in this process – an unusual practice in this context – the RIVM
campaign steered away from its focus on mothers’ and daughters’ choices and refers to ‘fami-
lies’ as decision-makers regarding vaccinations instead. Furthermore, our respondents (Inter-
views 17 and 18) indicate that they had not anticipated the role of social media, as a result of
which they were unable to steer public debate and could no longer solely rely on established
science-based policy instruments. This led to an increased investment in risk communication
skills and more attention paid to the role of social media (van Keulen et al. 2013). Once again,
this points to a lasting transformative effect of the vaccine on the infrastructure.
Second, while efforts were made to keep debates on vaccination and screening apart, as to
protect both programmes, HPV has been ‘weaved into’ the cervical cancer-screening pro-
gramme more recently. Starting in 2017, the screening programme will operate on the basis of
testing samples for the presence of high risk HPV in triage; only positive samples will then be
examined for cell changes (RIVM 2015). In addition, in an aim to increase participation rates
in the screening programme, the RIVM will offer self-sampling for high-risk HPV infections.
The self-sampling test is targeted at women who do not participate in the regular programme
(so-called ‘non-responders’) for, for example, religious or personal reasons. As a public health
practice, self-sampling not only has the potential to increase the construction of evidence justi-
fying HPV vaccination – it also speaks to the ability of Dutch public health infrastructures to
accommodate different publics in its approach.
Overall, the screening programme was technically set apart from the HPV-screening debate,
not only protecting the screening programme from the political upheaval, but also underscoring
the technical approach of Dutch public health protection. Again, this speaks to the strong insti-
tutional efforts invested in public health here, which stand in stark contrast to the reliance on
individual efforts in Austria. We shall explore the implications of these differences in our con-
cluding section below, as well as the consequences for the co-existing approaches of combat-
ing cervical cancer: vaccination and screening.
Discussion and conclusions
Efforts to introduce the HPV vaccine against the backdrop of existing cervical cancer screen-
ing programmes are reminiscent of historical efforts to make the Pap smear ‘good enough’
(Casper and Clarke 1998). In this process, conﬂict and dissent becomes concealed, and a tech-
nology becomes embedded in social worlds. Our paper takes up conﬂict and negotiation as an
object of analysis, and in doing so, mobilises the concept of ‘infrastructural friction’. With this
concept, we bring together STS and critical policy studies and are able to trace and analyse
the emergence of the HPV vaccine in Austria and the Netherlands.
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We ﬁnd two sets of frictions: ﬁrst, the temporal, technical, and social alignment between
two infrastructures – cervical cancer screening and primary prevention in national immunisa-
tion programmes – and, second, the infrastructural friction that occurred within NIPs when the
novel vaccine did not easily match established assessment criteria and prevailing concepts. In
Austria, policymakers invested strongly in tinkering with the vaccine, leaving the fragmented
screening and prevention infrastructures in need of reform. Opposition to the HPV vaccine
was continuously conﬂated with resistance to vaccination in general, and critics were rhetori-
cally sidelined to avoid unlocking the kind of debate witnessed in the early phase of HPV pol-
icy (Paul 2016). By transforming the vaccine into a vaccine ‘just like any other’ over time,
and having it administered by pediatricians, the vaccine was not only desexualised but also
disentangled from cervical cancer screening. The two public health infrastructures were at once
protected and kept apart. Our earlier observation that the two sets of emergent technologies are
treated separately in sociological scholarship thus reﬂects strategies of creating institutional
space for the new vaccine.
In the Netherlands, the early ‘rolling out’ approach and the reliance on biomedical knowl-
edge as the sole legitimate input for policy failed to convince – and perhaps even encouraged
– an increasingly critical citizenry. The HPV vaccine could not easily be embedded within the
solid and programmatic NIP infrastructure, nor could the debate be captured as an exclusive
expert matter. The ‘weaving in’ approach we observed, as well as the ‘inescapability’ of the
public health surveillance infrastructure reveal the efforts of policymakers to regain ownership
of both vaccination and screening matters while keeping the two apart. These efforts culmi-
nated in the creation of a separate infrastructure for HPV vaccination and increasing inclusion
of social-scientiﬁc expertise in policymaking.
Beyond these speciﬁc ﬁndings, the loose nature of Austria’s public health programme and
the programmatic and solid character of screening and prevention in the Netherlands have sev-
eral implications. First, in Austria, the relative strength of public health infrastructures contin-
ues to rely on individual efforts – those of patients, parents and professionals. At the same
time, the loose nature of public health also creates room for social, organisational, and regional
diversity or even pilot projects – as in the 2007 and 2008 regional experiments with HPV vac-
cination – and thus enables the emergence of different kinds of contextual alignments between
infrastructures and technologies. In contrast, the rather rigid nature of infrastructures in the
Netherlands may imply that only innovations that ‘ﬁt’ these infrastructures are able to emerge,
even if those are then more quickly absorbed than in other contexts, such as Austria. This
ought to be explored further in future comparative research. Third, the reliance on individual
efforts in Austria also implies that women can seek specialist care if they feel concerned. This
is virtually impossible in the Netherlands – where the programmatic nature of public health
limits, if not forecloses, individual initiative (for additional Pap smears) despite a clear discur-
sive trend towards personalised responsibility for health prevention and individual empower-
ment. Arguably, there is then a conﬂict between the biomedical statistics-based health policy
and the individualism invoked in contemporary policy discourse (cf. Blume 2006).
We conclude that, despite considerable differences in the reception of the vaccine and its
implementation across countries, neither infrastructure nor technology was left unchanged by
its emergence in political contexts. Our mobilisation of the concept of ‘infrastructural friction’
is not only helpful in bringing together disciplines – or perhaps social worlds, those of sociol-
ogy and critical policy studies. It also offers new tools in studying emerging technologies com-
paratively. Future research may then consider to what extent infrastructures ‘learn’ when new
technologies become adapted and adopted, and how not only technologies but also additional
social worlds (e.g. social scientists) become embedded in them.
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